Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Kymera Therapeutics (KYMR) Accumulated Depreciation & Amortization (2019 - 2026)

Kymera Therapeutics has reported Accumulated Depreciation & Amortization over the past 8 years, most recently at $24.1 million for Q1 2026.

  • Quarterly Accumulated Depreciation & Amortization rose 32.75% to $24.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $24.1 million through Mar 2026, up 32.75% year-over-year, with the annual reading at $22.1 million for FY2025, 37.67% up from the prior year.
  • Accumulated Depreciation & Amortization was $24.1 million for Q1 2026 at Kymera Therapeutics, up from $22.1 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $24.1 million in Q1 2026 and troughed at $4.6 million in Q1 2022.
  • The 5-year median for Accumulated Depreciation & Amortization is $10.5 million (2024), against an average of $12.9 million.
  • Year-over-year, Accumulated Depreciation & Amortization soared 88.26% in 2022 and then surged 32.75% in 2026.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $6.9 million in 2022, then surged by 51.46% to $10.4 million in 2023, then skyrocketed by 53.96% to $16.1 million in 2024, then surged by 37.67% to $22.1 million in 2025, then grew by 8.72% to $24.1 million in 2026.
  • Per Business Quant, the three most recent readings for KYMR's Accumulated Depreciation & Amortization are $24.1 million (Q1 2026), $22.1 million (Q4 2025), and $22.4 million (Q3 2025).